Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management (Q30250106)

13 June 2017

1 reference

title

Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management (English)

1 reference

13 June 2017

1 reference

Kumutnart Chanprapaph

series ordinal

1

1 reference

13 June 2017

Suthinee Rutnin

series ordinal

2

1 reference

13 June 2017

Vasanop Vachiramon

series ordinal

3

1 reference

13 June 2017

language of work or name

1 reference

24 May 2016

1 reference

American Journal of Clinical Dermatology

13 June 2017

published in

1 reference

13 June 2017

volume

17

1 reference

13 June 2017

issue

4

1 reference

13 June 2017

page(s)

387-402

1 reference

Dermatological toxicity associated with targeted therapies in cancer: optimal management

13 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

21 January 2018

Multi-kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Kinase inhibitors in the treatment of immune-mediated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Erythematous eruption of the palms and soles associated with mitotane therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Management of hand-foot syndrome induced by capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Epithelial-stromal interactions in basal cell cancer: the PDGF system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Application of a PDGF-containing novel gel for cutaneous wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Validation of the Japanese version of HFS-14, a disease-specific quality of life scale for patients suffering from hand-foot syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Prevention and management of adverse events related to regorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Efficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving Capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40257-016-0197-1

10.1007/S40257-016-0197-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

13 June 2017

1046772547

0 references

1 reference